Why Incyte Stock Was Tanking This Week

Eric Volkman, The Motley Fool

Fri, Mar 21, 2025, 8:56 AM 2 min read

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open.

On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa. This is a chronic and inflammatory skin condition that can result in scarring, among other complications.

In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count. Both of the tested doses achieved similar results.

Although the biotech touted this as a success, some analysts were expecting better, given the drug's encouraging performance in phase 2 trials. If eventually approved and commercialized, povorcitinib will have competition, particularly with UCB's well-established and Food and Drug Administration-approved Bimzelx.

Nevertheless, Incyte asserted that the phase 3 trials support its planned regulatory submission of its investigational drug.

Biotechs are always heavily dependent on their pipeline, even commercial-stage ones like Incyte that already have approved medicines on the market. Povorcitinib still might be approved, given its performance against the placebo; however, at the moment, it isn't looking like much of a breakthrough medication.

Before you buy stock in Incyte, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Incyte wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $726,481!*

Now, it’s worth noting Stock Advisor’s total average return is 835% — a market-crushing outperformance compared to 164% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of March 18, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Incyte. The Motley Fool has a disclosure policy.

Why Incyte Stock Was Tanking This Week was originally published by The Motley Fool